Objective: Transcatheter aortic valve implantation is a new method for the treatment of very-high-risk patients with aortic valve stenosis. Particularly in patients who have had previous cardiac surgery, the operative risk can be reduced. Nevertheless, this new procedure has some potential risks in these patients, due to the increased danger of endocarditis and in view of potential graft damage after previous bypass grafting or prosthesis damage after previous valve replacement, caused by wire manipulation or valve liberation. Methods: Between April 2008 and January 2010, 198 consecutive patients underwent transapical aortic valve implantation. Group A consisted of 158 patients without previous heart surgery and group B had 40 patients with previous heart operation (23 coronary artery bypass grafting, three aortic valve replacements, two mitral valve repairs, one replacement, and 11 combined operations). Although patients in group B (75 AE 11) were significantly younger than the ones in group A (80 AE 8) ( p = 0.003), the preoperative risk score was significantly higher in group B (group A -the European System for Cardiac Operative Risk Evaluation (EuroSCORE): 37 AE 18%; the Society of Thoracic Surgeons (STS) mortality score: 21 AE 16; group B -EuroSCORE: 53 AE 21%; STS mortality score: 29 AE 18) ( p < 0.001, p = 0.006). Results: The technical success rate was 99.5% (157/158) in group A and 100% (40/ 40) in group B. One patient in group A developed an annulus rupture. The postoperative echocardiographic examinations showed low transvalvular gradient due to the special design of the valve, without differences between the two groups. The 30-day mortality was 6.9% in group A and 5.0% in group B, and the 1-year survival was 77% and 74% in group A and group B, respectively (nonsignificant). Conclusions: Transcatheter valve implantation can be performed successfully after previous heart surgery. Particular care should be taken to achieve optimal valve position and not to damage grafts or prosthetic valves during manipulation with guide wires or valve positioning. #
Introduction
Transcatheter aortic valve implantation was developed in the early 1990s by Andersen et al. [1] . In April 2002, Cribier et al., for the first time, implanted an expandable aortic valve in a human through transvenous/transseptal access [2] , and in 2007 Walther et al. showed that transapical aortic valve implantation might reduce the risk of conventional surgical aortic valve replacement (AVR) in very-high-risk patients [3, 4] . Particularly in patients with previous cardiac surgery, the operative risk can be reduced as there is less surgical trauma. Nevertheless, previous coronary artery bypass graft (CABG) operations, AVR, or mitral valve surgery (MVS) pose unknown risks when this new procedure is performed.
In this study, we examine the surgical procedure and the postoperative course of patients undergoing transcatheter aortic valve implantation after previous heart surgery and discuss the potential pitfalls.
Materials and methods
Transapical aortic Edwards SAPIEN valve implantation (Edwards Lifesciences, Irvine, CA, USA) was performed between April 2008 and December 2009 in 198 patients at the Deutsches Herzzentrum (German Heart Institute) Berlin, Germany. During the same period, 32 transfemoral valve implantations (14 Edwards SAPIEN, 18 CoreValve (Medtronic CV, Luxembourg)) were performed. In all patients with reoperation, the transapical aortic valve implantation was chosen because of more precise valve handling and positioning. The procedures were performed in a hybrid operating room in a completely sterile environment and under fluoroscopic imaging with a monoplane angiography system. The surgical technique of transcatheter valve implantation was based on the procedure described by Walther et al. [3, 4] with the modification of transcatheter valve positioning and liberation under simultaneous angiography with contrast medium, not only to make a blind technique visible, but also to find optimal valve position and to reduce the risk of paravalvular leakage [5] .
Patient cohorts
This report is based on 198 multimorbid patients (with peripheral vascular disease, diabetes mellitus, pulmonary hypertension, etc.) presenting with severe aortic valve stenosis in advanced age (>70 years of age) and/or high preoperative risk assessment (logistic European System for Cardiac Operative Risk Evaluation (EuroScore) >20%) ( Tables  1 and 2 ). The procedure was also performed in patients presenting with logistic EuroScore of less than 20% and severe comorbidities (porcelain aorta, adipositas per magna, previous heart surgery, and left heart failure). All patients had significant aortic valve stenosis with tricuspid calcification of the valve. The diameter of the annulus was less than 24 mm.
Of the 198 patients in whom the procedure was performed, 158 had had no previous heart operation (group A). This group consisted mostly of women (75%) with a mean age of 80 AE 8.4 (range: 36-98) years. The mean Society of Thoracic Surgeons (STS) mortality score was 21 AE 16.3% (range: 3-86) and the EuroSCORE was 37 AE 18.3% (range: 6-97) [6] .
The second group (B) comprised 40 patients in whom the procedure was performed after previous heart surgery. Twenty-three patients had had previous coronary artery bypass grafting (CABG), three previous AVRs, eight combined AVRs and CABG, four MVSs, one combined MVSs and CABG, one double-valve replacement and CABG, and one MVS with CABG and apico-descending conduit (21 mm St. Jude Medical (SJM)). In this second group, there were more men than women (22/18). The mean age was 75 AE 10.6 (range: 37-86) years. The age of patients in group B (75 AE 11 (range: 37-86) years) was significantly lower than in group A ( p = 0.003). In contrast, the preoperative risk score was significantly higher in group B (EuroSCORE: 53 AE 21% (range: 22-96); STS mortality score: 29 AE 18 (range: 4-90); ( p < 0.001, p = 0.006)) (Tables 1 and 2). 
Pre-and postoperative evaluation
The pre-and postoperative examinations included clinical and laboratory examinations, electrocardiogram (ECG,) chest X-ray, transthoracic echocardiography, cranial computed tomography (CT), and CT of the chest and pelvis followed by vascular three-dimensional (3D) reconstruction. Preoperative coronary angiography and ultrasound examinations (Doppler) of the arteries and veins of the lower extremities and of the carotid arteries were performed. The Doppler examination allowed the detection of severe peripheral vascular disease. The CT of the chest was used to visualize the anatomical situation of the aortic root, and especially to measure the distance between the ostium of the coronary vessels and the native aortic valve. Both examinations were necessary to reduce the operative risk. If the CTof the pelvis showed no severe calcification of the vessels, the patients were evaluated for transfemoral valve implantation.
The echocardiographic data, the postoperative course, potential complications, and the late outcome were followed (Tables 3-5 ). In addition, a routine checkup was performed 1 month and 1 year after the operation. The data were compared between the two groups.
Statistical evaluation
All data analyses were performed using PASW Statistics, version 18.0 (SPSS Inc., Chicago, IL, USA). The Gaussian distribution of the data was controlled by the KolmogorovSmirnov test. Depending on the result, the measurements were analyzed by the Levene test for variance and by the unpaired sample t-test to find significances, or by the W-test, as appropriate. For survival analysis (Kaplan-Meier curves), the log-rank test was used. A p-value < 0.05 was considered to indicate statistical significance (Fig. 1 ).
Results
In all the patients, the technical procedure was performed using the standard technique [1, 3] , The technical success rate was 99.4% (157/158) in group A and 100% (40/40) in group B. In group A, 62 patients received a 23-mm and 96 patients a 26-mm Edwards SAPIEN valve. In group B, 17 patients had a 23-mm and 18 patients a 26-mm Edwards SAPIEN valve (Table 5 ). In nine patients (6%) in group A and in five patients (13%) in group B, the procedure was performed using the heart-lung machine because of high operative risk Due to the multimorbidity of the patients, they needed a long postoperative in-hospital stay. The mean length of stay on the intensive care unit (ICU) was 4.1 AE 6.7 days (range: 0.2-38 days) in group A and 4.6 AE 5.7 days (range: 0.2-23 days) in group B. There were no differences between the two groups ( p = 0.6) ( Table 5 ).
Echocardiographic data
Preoperatively, the echocardiographic data showed significant differences in left ventricular function between the two groups (Tables 3 and 4) . In group B, the left ventricular end-diastolic diameter (LVEDD) was significantly higher than in group A (LVEDD: group A: 48 AE 7.5 (range: 32-73) mm, group B: 53 AE 8.8 (range: 37-80) mm; p < 0.001) and the ejection fraction was significantly lower (group A: 51 AE 13.8% (range: 10-70); group B: 43 AE 14.6% (range: 10-65); ( p = 0.003)). Neither the aortic valve orifice area nor the diameter of the aortic annulus and the degree of valve regurgitation differed between the groups. Although the maximum transvalvular aortic valve gradient did differ between the groups, there were no differences in mean pressure (mean gradient -group A: 49 AE 13.7 (range: 12-83) mm Hg, group B: 42 AE 19.6 (range: 8-100) mm Hg; maximum gradient -group A: 73 AE 18.5 (range: 19-130), group B: 62 AE 26.3 (range: 15-140) ( p = 0.004)).
Postoperatively, the transvalvular gradient was low, due to the special design of the valve, and did not differ between the two groups (Table 4) . Central and paravalvular regurgitation are special characteristics in transcatheter valve implantation. Therefore, it is not surprising that postoperative echocardiographic examinations showed slight central incompetence in 23 patients in group A (15%) and in two patients in group B (5%). Minimal paravalvular leakage was observed in 46 (29%) patients in group A and 16 (40%) in group B ( p = 0.034). The paravalvular regurgitation was mostly of grade I or less than that; only in a few patients was it between grades I and II.
Cardiac pacemaker
In the case of postoperative atrioventricular (AV)-block degree III for more than 3 days, a cardiac pacemaker was implanted. In group A, 16 patients had previous pacemaker implantation (10 DDD, five VVI, one ICD) (10%) and 12 patients (8%) needed pacemaker implantation postoperatively. In group B, five patients had preoperative pacemaker (four DDD and one ICD) (13%) and no patient needed de novo implantation postoperatively.
Survival
The 30-day mortality was 6.9% in group A and 5.0% in group B, and the 1-year survival was 77% and 74% in group A and group B, respectively. The difference was not statistically significant (Table 5) . In group A, during the first 30 months, 11 deaths were observed. The reasons were heart failure in seven patients (in one case due to annulus rupture, in four patients due to left ventricular failure, and in two due to right ventricular failure (history of recurrent lung embolism)), followed by septicemia in three patients, and thrombosis of the arteria basilaris in one patient. The reasons for late death (23) were pneumonia (eight), followed by multiorgan failure (five), septicemia (four), carcinoma (two), kidney failure (one), stroke (one), bone fracture (one), and one sudden death (stroke, DD heart fibrillation).
In group B, two early deaths occurred. One patient died of heparin-induced thrombocytopenia type II with subsequent multiple embolisms and the other patient of septicemia following heart failure (preoperative cardiogenic shock with ejection fraction of 10%). The nine late deaths were due to septicemia (two), pneumonia (two), multiorgan failure (one), cervical fracture (one), gastrointestinal bleeding (one), stroke (one), and carcinoma (one).
Discussion
In patients with previous heart surgery, the operative risk is elevated during conventional AVR. The mortality ranged from 3% to 30% [7] [8] [9] . Although in more recent publications a lower mortality risk has been described [10] , this problem still exists, especially in patients with advanced age and increased STS and EuroScore. Transcatheter aortic valve implantation has been introduced to reduce the surgical risk.
Therefore, no experience as yet exists with this new technique in patients with previous CABG. For conventional AVR after bypass grafting, an early postoperative mortality of between 10.5% and 30% has been described [9, 11] . In our study, the experience with 23 patients with previous CABG demonstrated good feasibility. The risk of coronary obstruction due to incorrect valve positioning was reduced. Nevertheless, special care should be taken not to damage the proximal grafts during the introduction of guide wires, the pigtail catheter, or the 14-F soft sheath.
The increased preoperative risk for redo AVR has been shown by Christiansen et al. [12] . In his group of 63 patients with reoperation of the aortic valve, 44% of patients had postoperative complications and the 30-day mortality was 6.3%. In elderly patients with previous bioprosthetic AVR presenting with valve degeneration, a transcatheter valve implantation is a potential alternative, as shown by Khawaja et al. [13] . They implanted CoreValves (Medtronic, Luxembourg) in four patients with degenerated aortic prostheses with good early postoperative results and concluded that long-term follow-up will demonstrate the benefits and limitations of this technique. Earlier, in 2007, Walther et al. presented the feasibility of Edwards SAPIEN valve implantation in five Carpentier Edwards porcine aortic valves in a pig model [14] and in 2007 in humans [15] . Our experience showed good feasibility in these patients. In patients with previous aortic valve xenografts, the Edwards SAPIEN valve positioning can be easily performed using X-ray. Naturally, paravalvular leakage of and endocarditis on the degenerated aortic prosthesis are still contraindications. In most cases, the smaller Edwards SAPIEN valve is chosen due to the small inner size of the bioprosthesis.
Previous mitral valve replacement is still classified by the manufacturer as a contraindication for Edwards SAPIEN valve implantation. This can be explained by the increased risk of endocarditis, the potential mitral annulus pressure caused by aortic valve stent dilatation with increased risk of paravalvular leakage, the possibility of Edwards SAPIEN valve dislocation due to unsatisfactory stent anchorage, the potential direct contact between the two valves with inhibition of mechanical mitral leaflet mobility, and the danger of biological leaflet damage caused by transcatheter wires. The experience using the transcatheter technique for aortic valve implantation in patients with previous MRS is limited. A case report of an 84-year-old woman with previous mechanical bi-leaflet mitral valve replacement demonstrated the surgical feasibility of transapical Edwards SAPIEN valve implantation [16] . In this report, the authors recommended higher positioning of the aortic prosthesis. Our experience is with six patients with different techniques of previous MRS. The transcatheter wires should be introduced carefully so as not to touch the mitral prosthesis. Moreover, the 26-F transapical valve delivery system (Edwards) should be introduced into the left ventricular outflow tract just below the aortic valve so as not to damage a biologic mitral prosthesis during introduction of the crimped valve.
In our experience, in all patients with previous sternotomy, the apex localization for transapical access can be easily performed and is not more difficult than in patients with no previous operation. CT of the chest and echocardiography allows easy visualization of the anatomy. Nevertheless, special care should be taken not to damage the lung in the case of adhesions. Pericardial adhesions producing stronger tissue may be a reason for less postoperative bleeding, although the data showed no significant difference in this respect between groups A and B. The transcatheter valve positioning and liberation under simultaneous angiography with contrast medium (Berlin technique) allow exact valve positioning and a reduction of the risk of paravalvular leakage [5] .
Transapical aortic valve implantation in patients with previous heart surgery has been in practical use for 2 years, so that this report reflects the early experience. Nevertheless, previous sternotomy still represents an increased risk for secondary heart surgery. High-risk patients with previous surgery and needing AVR are optimal candidates for transcatheter valve implantation. Careful introduction of the transcatheter wires under fluoroscopy and echocardiographic monitoring and liberation of the Edwards SAPIEN valve using the 'Berlin addition' [5] are the keys for successful transapical valve implantation after previous heart surgery.
